INBRAIN Neuroelectronics vs Saluda Medical
Side-by-side comparison of AI visibility scores, market position, and capabilities
INBRAIN Neuroelectronics develops graphene-based brain-computer interfaces for AI-driven, adaptive neuromodulation; raised €30M Series B in 2024; targeting Parkinson's, epilepsy, and psychiatric disorders;
About
INBRAIN Neuroelectronics is a neurotechnology company founded in 2019 as a spin-out from the Catalan Institute of Nanoscience and Nanotechnology (ICN2) in Barcelona, Spain. The company develops minimally invasive brain-computer interfaces built on graphene — a single layer of carbon atoms with exceptional electrical conductivity, biocompatibility, and transparency to MRI imaging. INBRAIN's graphene electrodes enable higher spatial resolution neural sensing and more precise, adaptive stimulation than conventional metal electrodes used in implantable neurostimulators.
Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.
About
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.
AI Visibility Head-to-Head
Key Details
Also Compare
INBRAIN Neuroelectronics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.